Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables and boxes

abdominal obesity 169, 200
   cardiovascular disease outcome 173
disease risk 428
infertility 241
obstructive sleep apnea 248
risk assessment 270
testosterone levels 243
abdominal pain
   adolescents 416
   children 383, 396, 402
abdominal sagittal diameter 5, 6
aboriginal populations 429
cultural factors 437
   see also named peoples
acanthosis nigricans 270, 394
accelerometry 155
acromegaly
   obstructive sleep apnea 251
   weight gain 269
active neighborhoods 478
active transport 480
acute coronary syndromes 231
acylation-stimulating protein (ASP) 123
adenosine triphosphate (ATP) 151
skeletal muscle 123, 124
adenotonsillar hypertrophy 398
adipocyte triglyceride lipase (ATGL) 105
adipocytes 103–10
   adipokines 106–8
   brown 103–4
   hypoxia 109–10
   inflammation-related proteins 108–9
   intramuscular 118
   lipoprotein lipase deficiency 122, 123
   metabolism 175–6
   plasminogen activator inhibitor-1 secretion 177
   size 174–5
   white 104, 105
   secretory function 105–6
   adipokines 78–9, 106–8, 202
   adipose tissue secretion 119
   anti-inflammatory 204–5
   chronic inflammatory state 215, 216
   dyslipidemia 176–7
   energy balance 106, 107
   immunity role 108
   inflammation role 108
   insulin sensitivity 106, 108
   muscle metabolism 118
   secretion 213–14, 215
   adipokine 106
   adiponectin 79, 107, 119, 213, 215
   glucose homeostasis effects 177
   insulin resistance 178
   visceral fat syndrome 202–5
   visceral obesity 173
   weight loss 193
   adipose mass-fat relationship 74
   adipose tissue
      abdominal 169–71
      chronic inflammatory state 214–15
      distribution 169
      endocrine function 202, 213–14
      energy metabolism effects 119
      during exercise 125–6
      IL-6 production 177
      inflammation 108–9
      insulin resistance 213–16
      insulin sensitivity 210
      lipid storage function 176
      lipolysis 119
      lipoprotein clearance 122
      lipoprotein lipase 122, 123
      metabolic syndrome 213–16
      metabolism alteration by obesity 123
      NEFA release 128
      during exercise 125–6
      inhibition 121
      postprandial 122
      rate 118–19
      postabsorptive metabolism 118–19
      postprandial metabolism 121–3
      subcutaneous 17
      thigh 17–19
      subcutaneous compartment 176
      triacylglycerol concentration regulation 119
      visceral 17, 169–74
   adiposity, regional in children 375, 376
   adiposity signals 73, 74
   adipin 106
   adolescents
   abdominal pain 416
   adverse effects of rapid weight loss 416
   anxiety 403
   assessment 410
   bariatric surgery 415–16
   body fat distribution 393
   body weight loss maintenance 416
   cholelithiasis 402
   depression 403
   diabetes 399–400
   drug use 335
   eating behavior 403
   eating disorders 403, 416
   fat-free mass 393
   gastroesophageal reflux disease 401–2
   hepatic steatosis 20, 401
   metabolic syndrome markers 17
   natural weight gain in females 357
   prevention of obesity 410, 475
   protein-modified fast 414–15
   psychiatric diagnosis 403
   psychosocial complications 402–4
   puberty
      risk time for further weight gain 393
      staging 396
      response to being obese 403
      self-esteem 402–3
      sibutramine use 329
      subcutaneous adipose tissue 17
      weight stigma 32–3
      reduction 34
   adoption studies, fat mass heritability 83
   adrenceptors 156
   see also beta-adrenceptors
   adrenocorticotropic hormone (ACTH) deficiency 89
   advertising 462
   advocacy 481
   aerobic exercise 159, 321
   aerobic fitness 320
Index

African–American people
children 430
environmental factors 437
age 10, 11
obesity prevalence 171
obstructive sleep apnea 250
visceral adipose tissue accumulation 169–71
see also adolescents; children; elderly people; infants
aging
body composition 126
insulin resistance 210
visceral fat accumulation 205
agriculture, development 441
air displacement plethysmography (ADP)
American paradox 441
alcohol consumption 289–90
alcohol, substrate metabolism 75
Albright hereditary dystrophy 85
alimentary crash 107, 108
anxiety, adolescents/children 403
antipsychotics, atypical 383
anthropometric measures 4–6
antenatal care 479
anorexia nervosa 193
antenatal care 479
apolipoprotein(s) 168
apolipoprotein A-1 (apoA-1) 168, 169
apolipoprotein B (apoB) 167, 168, 169
apolipoprotein E (apoE) 167, 168
apotransferrin 19, 25
body image effects 344
apnea
entral 236, 247
see also obstructive sleep apnea
apnea/hypopnea index (AHI) 253, 254
body position 256
apolipoprotein(s) 168
apolipoprotein A-1 (apoA-1) 168, 169
apolipoprotein B (apoB) 167, 168, 169
visceral obesity 172
apolipoprotein E (apoE) 167, 168
appetite
cascade 135–6
cephalic phase 136
drive 140–1
ghrelin effects 140
hedonic processes 141–4
homeostatic processes 141–4
neuroimaging of homeostatic
interactions 142–3
neuromodulators 139
signalling systems 139
see also hyperphagia; overeating; satiety
appetite control 44, 134–5, 138–40
episodic signals 136–8
phenotypes 144–5
resistant phenotypes 145
signals 136
susceptible phenotypes 145
appetite suppressants 291, 330
arm circumference 3
atherosclerosis
CRP levels 204–5
inflammation 231
plaque 204, 231
atrial fibrillation, stroke risk 235
austerity 44
automation, work environment 443
Bardet–Biedl syndrome 85, 396
bariatric surgery effects 344
children 399
atherosclerosis
bias against obesity 25–34
anti-fat prejudice 48, 50–2
bias against obesity 25–34
anipsychotics, atypical 383
anxiety, adolescents/children 403
apelin 107, 108
be Active Eat Well program (Colac, Australia)
476–7
behavior chain 302
behavior modification/treatment 271–2, 290,
301–10
children 410, 411–12, 413
cognitive behavioral therapy 371
cognitive restructuring 303
commercial programs 386, 309
components 302
diet 303–4
dissemination 308–9
duration 306
food intake 303–4
liquid meal replacements 304
long-term weight control 306–7
pharmacologic intervention combination 308
physical activity 480
importance 307–8
weight control 305–6
rewards 301–2
schools 475
self-monitoring 302–3
stimulus control 303
structure 306
training of healthcare professionals 371
transport 480
benign intracranial hypertension 402
benzodiazepines, obstructive sleep apnea 256
benzphetamine 329–30
beta cells, pancreatic
free fatty acid exposure 212
incretin effect 212
insulin secretion 211–13
pre-/post-natal malnutrition 213
beta-adrenoceptors 78
catecholamine stimulation of energy expenditure
160–1
bias against obesity 25–34
anti-fat prejudice 48, 50–1
bicarbonate–urea energy expenditure methods
153, 154
bigness, preference for 43
biliopancreatic diversion procedure (BPD) 340,
341, 346–7
duodenal switch 340, 341, 346–7
malabsorption 347
outcomes 342
binge-eating 31
disorders 320
weight cycling 353
weight loss maintenance 355–6
bio-electric impedance analysis (BIA) 15
children 376, 377
biologic factors 11
Black, Joseph 151, 152
blood pressure
exercise training 319–20
reduction 232
see also hypertension
Blount disease 401
BOD-POD 6
body composition
aging 126
body energy content 161

488
Index

cardiac fat, visceral 20, 21
cardiovascular disease 228–37
  burden 432, 433
  children 397–8
  exercise 236
  gender differences 60
  obstructive sleep apnea 253–4
  outcome in abdominal obesity 173
  physical fitness 236
  risk 8, 11, 230–1
  childhood obesity 394, 397–8
  dyslipidemia 167–8
  gender differences 60
  physical activity 160
  visceral obesity 200–2
  weight gain 269
  worldwide epidemic of obesity 240
  care delivery systems, children 416–19

Care Model 416–19
  Center for Science in the Public Interest 481
  central apnea 236, 247
  central obesity 215–16
  abnormal fatty acid re-esterification 188–9
  children 384
  free fatty acids 216
  metabolic syndrome 217
  obstructive sleep apnea 248
  see also visceral obesity
  cerebrovascular disease 251, 254
cetilistat 335
cerebrovascular disease 251, 254
  obstruction 236, 247
  prevention of obesity 479

Childhood Obesity Action Network 419
  children
  0–2 years old 92–3
  weight status 380
  2–3 years old 93
  abdominal pain 383, 396, 402
  adverse effects of rapid weight loss 416
  African–American 430
  anthropometric measures 376, 384
  anxiety 403
  assessment 381–7, 410
  asthma 399
  bariatric surgery 415–16
  belonging to obese family 392–3
  benign intracranial hypertension 402
  beta cell defects 213
  BMI 93, 376–7
  centiles 377, 378
  cut-offs 377

  reference populations 378–80
  BMI-for-age
    assessment 384
  growth charts 377, 378–9, 380
  body fat measures 375–6
  body image 403
  body size preference 45
  body weight loss maintenance 416
  breathlessness 396
  bronchospasm 399
  cardiac abnormalities 397
  cardiovascular disease 397–8
  risk 394, 397–8
  care delivery systems 416–19

  central adiposity measures 384
  cholestithiasis 402
  classification of obesity 375–81
  community interventions 419
  complications of obesity 395–404
  comprehensive multidisciplinary intervention 409
  congenital leptin deficiency 86–8
  consequences of obesity 392–5
  adult morbidity/mortality 393–4
  adult obesity 392
  cutaneous striae 396
  depression 403
  diabetes 399–400
  diabetes mellitus 209, 433
  diet
    aggressive therapy 413–15
    assessment 386
    change 418
  disease burden 433
  disturbed body image 403
drug therapy 335, 415
  DXA 93–4, 375, 376, 377
  early origins of obesity 94
  eating behavior 403
  eating disorders 403, 416
  endocrine disorders 399–401
  exercise and bronchospasm 399
  family readiness for change 386–7
  fat distribution 391
  food advertising 462
  food marketing 481
gastroesophageal reflux disease 401–2
  gastrointestinal tract disorders 401–2
  gender impact on obesity risk 432
  genetic defects 402
  global comparisons of obesity 378–9
  global pandemic of obesity 431–2
  healthcare professionals’ attitudes 385
  healthcare provision 395
  heat intolerance 395
  heat rash 395–6
  hepatic steatosis 401
  hospital setting 395
  hyperinsulinemia 394
  hypertension 232, 397
  insulin resistance 394
  laboratory assessment 385
  lifestyle assessment 385–7
  medical history 383–4
  metabolic syndrome 397–8
  morbidity
    minor medical significance 395–6
    significant medical importance 396–402
  musculoskeletal discomfort 396
  neurologic disorders 402
  nonalcoholic fatty liver disease 383, 401
  obesity
    definition 375, 377, 427
    hypertension association 232
    increase 452–3
    measurement 92–4
    rates 454
    secondary to other disease states 382–3
  severe 380
  targets 453
  obstructive sleep apnea 398
  orlistat use 331, 415
  orthopedic morbidity 401
  parental failure to recognize obesity 395
  PEAPOD 93–4
  physical activity 418
  assessment 386
  bronchospasm 399
  parental perceptions of environment 447
  physical examination 385
  Pickwickian syndrome 398–9
  plump 45
  polycystic ovarian syndrome 382, 383, 400–1
  POMC deficiency 88–9
  Prader–Willi syndrome 84
diet 290–1
  prevention of obesity 410, 475
  prevention plus approach 409
  pseudo-gynecomastia 396
  psychiatric diagnosis 403
  psychologic disorders 383
  psychologic effects of labeling 381
  psychologic health 395
  psychosocial complications 402–4
  puberty as risk time 393
  puberty staging 396
  pulmonary embolism 399
  reference standard comparisons 379–80
  respiratory disorders 398–9
  response to being obese 403
  school-based interventions 419
  screening for obesity 381
  self-esteem 402–3
  self-management 417, 418
  sibutramine use 329, 415
  skin
    cutaneous striae 396
    lesions 395–6
    skinfold thickness 376, 377
  sleep disorders 383
  sleep-disordered breathing 398
  small genitalia in boys 396
  social deprivation 44
  socialization 52
  socio-economic status 432
  stigma of obesity 402
  structured weight management 409
  terminology used by healthcare professionals 385
  tertiary care intervention 409–10, 411–12, 413–16
  therapeutic encounter initiation 408
  tiredness 396
  treatment of obesity 408–19
  TV advertising 481
  vascular disease 397
  very low calorie/energy diets 277
  weight stigma 32–3
  gender differences 61
  reduction 34
  weight-for-height indices 376–7
  WHO growth standards 380
  see also adolescents; infants

490
Index

cholecystectomy, children 402
cholecystokinin (CCK) 72–3, 189, 190
satiety 136–7
weight loss 193
cholecystokinin receptors (CCKR) 189, 190
cholelithiasis adolescents/children 402
weight loss association 416
cholesterol cardiovascular risk 231
exercise training effects 319
plasma levels 167–8
reduction 231
reverse transport 167
visceral obesity 172
cholesteryl ester transfer protein (CETP) 168, 175
computed tomography (CT) 16–20
colonic cancer, adipose tissue inflammation 108
Common Agricultural Policy (EU) 460
colonic mucus 289
colon cancer, colorectal 225–7
colon cancer, saturated fat 281
chronic obstructive pulmonary disease 255
circulatory disorders
visceral obesity 201
see also cardiovascular disease
cholangiocarcinoma 238
liver transplantation 222–3
NASH progression 219
classic conditioning 301, 303
clinical management programs, prevalence reduction 475–6
cognitive behavioral therapy (CBT), behavior modification 371
cognitive factors, exercise 321
cognitive restructuring 303
cognitive world 464, 466
Colac Be Active Eat Well program 476–7
cold, resting metabolic rate 157
cold-induced thermogenesis 70
collaborative networks 477
colon cancer, adipose tissue inflammation 108
Common Agricultural Policy (EU) 460
community demonstration programs 475
case study 476–7
evaluation 477
community interventions 419
community-based management programs 475, 476
collaborative networks 477
monitoring 482
computed tomography (CT) 16–20
anthropometric measurement assessment 21
body fat measure 375, 376
fat storage 4
liver density 19–20
skeletal muscle measurement 19
computer games 444–5
conception, maternal diet 96
congenital anomalies 242
congenital leptin deficiency 86–8
congestive heart failure 235–6
hypertension 232–3
consumerist ethics 457
consumers 461
consumption, sustainable 461
continuing professional development 368–9
continuous positive airway pressure (CPAP), nasal 237
mandibular advancement device alternative 258
obstructive sleep apnea 231, 252, 254, 255, 257
with daytime respiratory failure 259
controlled ovarian hyperstimulation (COS) 241–2
cooking methods 289–90
Prader–Willi syndrome 291
coping strategies
body weight loss 356–7
stigma 32, 33
cor pulmonale 247
coronary artery calcification 231
coronary heart disease (CHD)
adiponectin levels 204
anti-inflammatory adipokine 204–5
atherosclerotic 231
high-protein diet 280
mortality 7
nonobese patients 202
physical activity 160
risk with dyslipidemia 167–9
fat distribution 230–1
sudden death risk 229
visceral obesity 202
corporate social responsibility 462
corticosteroids 383
counseling skills 371
C-reactive protein (CRP) 171–2
atherosclerosis risk 204–5
ischemic heart disease 173
obstructive sleep apnea levels 254
cultural influences 50–2
physical activity 436–7
culture 41–53, 456
complexity 42
definition 41
environmental factors 43–50
evolution 41–2
medicalized obesity 49–50
prejudice 48
slim ideal 46–7, 48
societal transitions 464
Western societies 46–7
Cushing syndrome
childhood obesity 382
obstructive sleep apnea 251
weight gain 269
cycling 445, 462
active transport 480
promotion 474
dairy products 289
DDP-4 inhibitors 222
decision support 417
dehydration, bariatric surgery 285
delivery system design 417
demographic factors 10–11
densitometry 4, 15–16
depression 320
adolescents 403
bariatric surgery effects 344
body weight loss/reduction 358–9
children 403
gender differences 61–2
weight stigma 31
deprived communities, supermarkets 447, 448
developed world
desirable body size 43
socio-economic status 44
developing countries
desirable body size 43
socio-economic status 44
developmental determinants 95–8
clinical implications 98–9
postnatal 96–7
prenatal 95–6
pre-/post-natal factor combination 97–8
public health implications 98–9
developmental origins of health and disease (DOHaD) 94
modifiable developmental determinants 95–8
studies 94
diabetes mellitus, type 2 7, 108
adiponectin levels 203
adolescents 399–400
bariatric surgery after 342–3
beta cells 211–13
BMI 209
increase 432
burden 432, 433
central fat distribution 209
children 209, 399–400, 433
epidemiologic associations with obesity 208–9
exercise training impact 319
incretin defects 222
insulin resistance 318–19
insulin secretion impairment 211–13
natural history of progression 209–10
obstructive sleep apnea 255
orlistat 331
pathogenesis 208–13
physical activity 160
prevalence worldwide 432, 433
risk 8, 11
gender differences 60
thigh circumference 18
risk factors 209
sibutramine use 328–9
treatment 222
weight gain 269
weight loss impact 343
worldwide epidemic of obesity 240
see also gestational diabetes; insulin resistance
diet 70
aggressive therapy in children 413–15
Americanization 454
assessment in children 386
bariatric surgery 285–6
behavioral treatment 303–4
built environment 447–8
children 418
aggressive therapy 413–15
assessment 386
commercial programs 286, 309
cycle 284
energy deficit 276–9
energy density 281
energy intake 281
fashion industry 51

exercise 313–22
24-hour energy expenditure 315–16
acute and 24-hour substrate utilization 317–18
adipose tissue metabolism 125–6
aerobic 159, 321
aerobic fitness 320
blood pressure reduction 234–5
bronchospasm in children 399
cardiovascular disease 236
cognitive factors 321
dietary restriction combination 314
diet-induced thermogenesis 315
energy balance 315–18
energy expenditure 315
energy intake 316–18
health-related well-being 320
intensity 321, 322
mental health 320
metabolic fuels 123–6
mode 321
obesity treatment 221
obesity-related morbidity/mortality 318–20
prescription 321
programmed activity 305
programs 271
risk 322
skeletal muscle metabolism 123–5
substrate utilization 317–18
visceral fat accumulation prevention 205,
weight maintenance 306
weight management recommendations 320–2
weight reduction 314
whole-body metabolism 123
see also physical activity
exercise training 315
blood lipid effects 319
blood pressure effects 319–20
diabetes impact 319
insulin resistance 318–19
insulin sensitivity 319
substrate utilization 318
exercise-related signals 74
extramyocellular lipid (EMCL) 19

fast foods, fat content 478–9
fast-food companies 459
fast-food outlets 448, 478–9
fast-food restaurants 442, 448
fasting conditions 117–20
fat, body
abdomen 248
chest 248
distribution 11 (see also abdominal obesity; android obesity; central obesity; visceral fat accumulation; visceral fat syndrome; visceral obesity)
cardiac risk 230
children 393
diabetes risk 209
evolution 42
gender differences 59
gynoid obesity 169
epicardial 20, 21
excess 6–8, 11
location 3
lower 42
measures for children 375–6
oxidation 317–18
percentage 3
storage
evolution 42
lower 42
measurement 4–6
regulation in white adipose tissue 123
upper 42
upper 42
fat, dietary
absorption-reducing drugs 330–2
content of foods 480
density of food 305
fast foods 478–9
intake
decline 441
hunger relationship 144–5
reduction 478–9
low energy-density diet 305
low-fat diets 279, 304
moderate-fat diets 279–80
storage 442
sudden death risk 229
thermic effect of food 158
fat mass, heritability 83
fat oxidation 75
fat tolerance 121
fat-free mass
adolescence 393
exercise effects 314
resting metabolic rate 155–6
fattening practices 43
fatty acids
abnormal re-esterification 188–9
dietary and sudden death risk 229
LPL-derived 123
oxidation 74, 117–18
release
in adipose tissue 105, 122
by lipoprotein lipase 122

skeletal muscle
postprandial utilization 121
uptake 118
see also free fatty acids; nonesterified fatty acids (NEFA)
female diseases 62
femur, slipped capital femoral epiphysis 401
fenfluramine, phentermine combination 335
fertility 240–4
puberty 400
see also infertility
fetal programming 430
fetus
malformations 242
nutritional programming 62
fibrinogen 172–3
fitness 51
flavonols, thermic effect of food 158
fluoxetine 332
FMRI gene mutations 85
food
advertising of children’s 462
availability 447
budget 436
cooking methods 289–90
cost 436, 442
distribution 480
diversity availability 447
eating out 442
energy density 442, 448, 480, 481
environment 441–2
etiology of obesity 41–2
health claims 481
labeling 480–1
levies 480
liking constructs 143–4
marketing to children 462, 481
nutrition claims 481
palatability 141, 142, 442
portion size 442
portion-controlled 303–4
price 447
pricing 480
provision equality 447–8
restriction in Prader–Willi syndrome 290–1
thermic effect 76, 151, 157–8, 161
types 289–90
value added 442
variety 289
wanting constructs 143–4
see also diet
food industry, multinational 52

food intake
amino acid levels 73
assessment 287
behavior control 135–40
behavioral treatment 303–4
body weight loss maintenance 355
control 71–5
integrated models 75
decisions 440
drugs reducing 327–30
energy expenditure 157–8
integration 79–80
medicalization of obesity 49
resistance to 51
Mediterranean diet 304, 305, 454
melanin-concentrating hormone (MCH) 72
melanocortin-concentrating hormone receptor 4 (MC4R) 86
mutation 139
alpha-melanocyte-stimulating hormone (MSH) 86
men body as process 47
body size preference 43, 47
infertility 45
westernization 45
menarche 400
menstrual cycle 62
disorders 241, 383
puberty 400
resting metabolic rate 157
mental health
body weight loss 351–2, 358–9
exercise effects 320
weight cycling 353
mental retardation 382
metabolic adaptation 76
metabolic disorders, visceral obesity 200–2
metabolic equivalent (MET) 321, 322
metabolic fuels 115–27
adipose tissue postabsorptive metabolism 118–19
dietary manipulation 126–7
exercise 123–6
fasting conditions 116–20
fluxes 117–18, 119
muscle postabsorptive metabolism 117–18
postabsorptive conditions 116–20
postprandial conditions 120–3
weight-stable obesity 117
whole-body postabsorptive metabolism 116
metabolic inflexibility 127, 175
metabolic states, fasting/postabsorptive conditions 117–20
metabolic syndrome 108, 201–2
adipose tissue 213–16
adolescent markers 17
cardiometabolic risk 174
central obesity 217
children 397–4
diagnostic criteria 216–17
glycemic index of foods 282
proinflammatory/prothrombotic component 171
screening tool 174
treatment 222
very low calorie/energy diet 279
visceral obesity 174
metabolism
amino acids 118
oxidative 124
postabsorptive 117–18
postprandial 120–3
see also resting metabolic rate (RMR)
metformin
diabetes treatment 222
polycystic ovarian syndrome treatment 401
weight reduction 333–4
microgen 396
microsomal triglyceride transfer protein (MTP) 205
migrants, westernization of diet/lifestyle 45, 82
mitazapine 259
miscarriage 240, 242
risk 62
mitochondrial dysfunction 188
mitogen-activated protein (MAP) kinase, insulin activity 187
modafinil 259
modernization 42
mono-naturated fatty acids (MUFAs) 279–80
moral panic 52
motivation, body weight loss 357
assessment 270
autonomous 358
multidisciplinary teams 417
muscular work 69
efficiency 77
musculoskeletal discomfort, children 396
myocardial fat 20
myokines 106–7
naltrexone, bupropion combination 335
National Association to Advance Fat Acceptance
nutrition claims for foods 481
education of healthcare professionals 366–72
signposts 415
training of healthcare professionals 370–1
Nutrition Transition 456
nutritional factors, energy expenditure 157–8
nutritional status, changes 426
obesity
children’s targets 453
chronic condition 360
classification 270
definition 3
children 375, 377, 427
children 0–2 years 92
determinants 10–12
early origins 94
etiology 433–4
measured 8–10
prevalence 9, 10, 10–11
reduction 475–6
reduction targets 453
self-reported 6–10
status 8–10
under-reporting 9–10
worldwide epidemic 240
see also epidemic of obesity; management of obesity; pandemic of obesity, global; prevention of obesity; stigma of obesity; treatment of obesity
obesity hypventilation syndrome 248–9, 259
obesity map 455
obesity syndromes
human monogenic 86–9
pleiotropic 83–5
obesity treatment
long-term strategies 361
programs 360
targets 360–1
obesogenic environment 440
obesogenic factors 471, 472
obstructive sleep apnea 201, 228, 237, 246–60
adenotonsillar hypertrophy 398
age 250
atrial fibrillation prediction 235
bariatric surgery effects 344
body position 256
cardiac arrhythmias 230
cardiovascular risk 231
central obesity 248
children 398
comorbidity 251
congenital conditions 251
consequences 253–5
continuous positive airway pressure 231, 254, 255, 257, 259
with daytime respiratory failure 259
definition 237, 246
diagnosis 252
epidemiology 249–51
familial factors 251
gender 250–1
 genetic factors 251
hypertension risk 237
inflammation 231
left ventricular hypertrophy 234
maxillofacial factors 251
neck circumference 270
obesity role 248
pathogenesis 247–9
pharmacologic treatment 259
prevalence 237
pulmonary hypertension 237
sudden death risk 230
surgical treatment 258–9
weight loss 255–6
occupation, physical activity 443–4
ovaries 242
operant conditioning 301–2, 303
oral hypoglycemic agents 383
orexin, nonexercise activity thermogenesis 159
orexin A 72
orexin B 72
orlistat 273, 330–2
behavioral treatment combination 308
children 331, 415
diabetes 331
efficacy 330–1
pharmacology 330–1
safety 331
sibutramine combination 331–2
orthopedic morbidity, children 401
ovarian dysfunction, bariatric surgery effects 343
overeating
 deliberate 126
 highly palatable food 141, 142
 see also hyperphagia
overlap syndrome 255
overweight, classification 270
ovulatory failure 62, 241
oxidative metabolism 124
oxidative stress
 insulin resistance 188
 obstructive sleep apnea 231
oxygen 151
 see also hypoxia
oxygen, maximal uptake (VO2max) 321, 322
oxygen consumption (VO2) 152, 153–4
oxyntomodulin 192, 195
Pacific Island people see Polynesian people
Paleolithic ancestors 441
energy expenditure 443
pallatability of food 442
overconsumption 141, 142
pancreas 192–3
amylloid deposits 212–13
beta cells 211–13
pancreatic polypeptide (PP) 192–3, 195
pandemic of obesity, global 425–37
adults 427–32
causal pathways 433–7
children 431–2
country-specific prevalence 427, 428–9, 430
disease burden 432–3
economic growth 434
food market globalization 434
physical activity 436–7
prevalence 427, 428, 429
scope of problem 427–32
see also epidemic of obesity
parental bias 27
parenting style 413
parents
environmental perceptions 447
failure to recognize children’s obesity 395
prevention of obesity 477
Parents’ Jury 481
patient assessment 269–70
PEAPOD, children 93–4
diabetes treatment 222
personal responsibility, obesity 26
personality, body weight loss/reduction 358
pharmacologic drugs
appetite-suppressing 330
behavioral treatment combination 308
children 335, 415
weight gain 383
in clinical trials 334–5
CNS acting 327–30
combination use for weight control 331–2, 335
energy expenditure increase 335
fat absorption reduction 330–2
food intake reduction 327–30
not generally approved for obesity treatment 332–4
sympathomimetic 329–30
weight gain association 269, 270, 383
weight loss 273, 327–35
pharyngeal airway 248
phenidimetrazine 329–30
phentermine 329–30
drug combinations 335
phlogiston theory 151
physical activity 313–22
aerobic 159
behavior modification 480
body weight gain 313
loss maintenance 354–5
built environment 446–7
changes 442–5
children 386, 418
assessment 386
musculoskeletal discomfort 396
parental perceptions of environment 447
cultural influences 436–7
decisions 440
decline 441
energy balance 160, 316–18
energy expenditure 69, 158–60, 443–5
energy intake 160
environmental influences 442–5, 446–7
fuel utilization 159
global pandemic of obesity 436–7
importance 307–8
leisure-time 444
monitors 153
musculoskeletal discomfort in children 396
occupation 443–4
prevention of obesity 478
programmed 305
programs 271
resting metabolic rate 159–60
societal transitions 464
sociocultural variables 436–7
spontaneous 70, 76, 77
supportive neighborhood environment 446–7
training of healthcare professionals 371–2
types 159
weight control 305–6
work environment 443–4
 see also exercise
physical activity multiplier 155
physical fitness
aerobic 320
cardiovascular disease 236
mortality risk 228–9
physical inactivity, body weight gain 313–14
physicians see healthcare professionals; medical profession
physiologic conditions, weight-stable
patients 116–26
physiologic world 464, 466
Pickwickian syndrome, children 398–9
Pierre–Robin sequence 251
Pima Indians 82
adiponectin levels 203
energy expenditure 161
pioglitazone 222
plasminogen activator inhibitor (PAI) 172
Index

Voit, Carl von 151, 152
volume overload, left ventricle 233
vomiting, bariatric surgery 285
von Willebrand factor 172–3

waist circumference 3, 4–5, 5–6
  assessment by imaging techniques 21
  cardiovascular risk 11
  central obesity 216
  cut-offs 7–8
  morbidity/mortality risk 8
  patient examination 270
waist-to-hip circumference ratio (WHR) 3, 216
  adipose tissue distribution 200
  coronary event risk 230
  visceral adipose tissue accumulation 169
  waist-to-hip ratio 3, 4, 6
    assessment by imaging techniques 21
  wakefulness 246
  walkability 446, 447
  walking 445, 462
  active transport 480

built environment 446
recreational 447
to school 461, 462, 478
transport 447
wanting constructs for food 143–4
weight see body weight
weight bias see bias against obesity; stigma of obesity
Weight Locus of Control Scale 357–8
Weight Loss Readiness Test 357
Weight Watchers 286, 309
weight-for-height index, children 376–7
weight-for-length measurement, infants 92–3
weight-for-stature 377
weight–height (W-H) index 377
westernization 45, 82
white adipose tissue (WAT) 103
  characteristics 104–5
  distribution 116
  fat deposition/mobilization routes 125
  fat storage regulation 123
  inflammation-related proteins 108–9
  secretory role 106
whole-body postprandial metabolism 120–1
women
  bodies as objects 46–7
  body size preference 43, 46
  cultural predictors of ideal body shape 44
  infertility 241–2
  object construct 46–7
  poverty 44, 45
  slim ideal 46–7
  socio-economic status 44
  westernization 45
work environment 434
  automation/mechanization 443
  physical activity 443–4
World Health Organization (WHO)
  child growth standards 380
  global pandemic 425–7
zonisamide 333
drug combinations 335